Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ultragenyx Pharmaceutical Inc.

www.ultragenyx.com

Latest From Ultragenyx Pharmaceutical Inc.

US FDA's Stein To Sponsors: New Leadership From OND Reorganization Won't Change Your Development Plans

Office of New Drugs Director Peter Stein told sponsors during a panel discussion that they will be able to continue agreed upon development programs despite leadership changes arising from the OND reorganization; industry speakers excited, but also have some reservations, about the new OND.

Leadership FDA

Individual Endpoints Pose Challenge For US FDA In Review Of Rare Disease Drug

FDA reviewer describes difficulties in reviewing application for Mepsevii for Sly syndrome; the experience provides perspective for other companies seeking to use novel endpoints.

Drug Review FDA

Finance Watch: Forma Raises $100m In Quest To Become A Sickle Cell Leader

The firm reorganized to focus on hemoglobinopathies and cancers after Celgene ended a multi-drug partnership. Also, Flagship funds a gene therapy start-up and brings in a business development veteran, Ultragenyx raises $320m in a royalty deal and Paratek secures up to $285m from BARDA. 

Financing Business Strategies

Keeping Track: A Novel Approval For Fluorodopa F 18, A Tentative Approval For Vumerity, And A Missed Goal Date For Zilretta

The latest drug development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ultragenyx Pharmaceutical LLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ultragenyx Pharmaceutical Inc.
  • Senior Management
  • Emil Kakkis, MD, PhD, Pres. & CEO
    Shalini Sharp, EVP, CFO
    Thomas Kassberg, EVP, CBO
    Camille L Bedrosian, MD, EVP, CMO
    Erik Harris, EVP, Chief Commercial Officer
  • Contact Info
  • Ultragenyx Pharmaceutical Inc.
    Phone: (415) 483-8800
    60 Leveroni Ct.
    Novato, CA 94949
    USA
UsernamePublicRestriction

Register